FDA Approval Insights: Avapritinib in Indolent Systemic Mastocytosis

0 Visualizzazioni· 07/10/23
OncLive® On Air
OncLive® On Air
0 Iscritti
0
In

Dr Gotlib discusses the significance of the FDA approval of avapritinib in indolent systemic mastocytosis, key findings from the PIONEER trial, and the quality of life benefits that avapritinib provides for patients in this population.

Mostra di più

 0 Commenti sort   Ordina per


Avanti il prossimo